NCT06761976 2026-03-30
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
Bayer
Available
Clinical Trials
7 trialsNCT02632994 2025-09-29
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Eli Lilly and Company
Available
NCT06048081 2025-09-10
Early Access Program for Zolbetuximab
Astellas Pharma Inc
Available
NCT06980506 2025-05-22
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT06980519 2025-05-22
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
Monopar Therapeutics
Available
NCT05572970 2025-04-30
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Agenus Inc.
Available
NCT05491928 2022-09-01
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Matrix Biomed, Inc.
Available